FIS1 and hepatocellular carcinoma: In addition, we examined the effect of Fis1 pY38 on cell growth, cell cycle, apoptosis, and drug resistance to olaparib or sorafenib in HCC cells, and found no significant differences in these aspects (Supplementary Fig. S4j–m).